Overview of current adipose-derived stem cell (ADSCs) processing involved in therapeutic advancements: flow chart and regulation updates before and after COVID-19
| Autor: | Gabriel Malka, Loubna Mazini, Mohamed Ezzoubi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Standardization
Medicine (miscellaneous) Cell Separation Review Bioinformatics Biochemistry Genetics and Molecular Biology (miscellaneous) Regenerative medicine lcsh:Biochemistry Cell therapy Patient safety ADSCs Humans Medicine lcsh:QD415-436 HCT/P 351-361 Progenitor cell ATMPs lcsh:R5-920 business.industry Stem Cells Regeneration (biology) COVID-19 Cell Biology cGMP medicine.anatomical_structure Adipose Tissue Molecular Medicine Bone marrow Stem cell lcsh:Medicine (General) business Stem Cell Transplantation |
| Zdroj: | Stem Cell Research & Therapy Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-17 (2021) |
| ISSN: | 1757-6512 |
| DOI: | 10.1186/s13287-020-02006-w |
| Popis: | Adipose-derived stem cells (ADSCs) have raised big interest in therapeutic applications in regenerative medicine and appear to fulfill the criteria for a successful cell therapy. Their low immunogenicity and their ability to self-renew, to differentiate into different tissue-specific progenitors, to migrate into damaged sites, and to act through autocrine and paracrine pathways have been altogether testified as the main mechanisms whereby cell repair and regeneration occur. The absence of standardization protocols in cell management within laboratories or facilities added to the new technologies improved at patient’s bedside and the discrepancies in cell outcomes and engraftment increase the limitations on their widespread use by balancing their real benefit versus the patient safety and security. Also, comparisons across pooled patients are particularly difficult in the fact that multiple medical devices are used and there is absence of harmonized assessment assays despite meeting regulations agencies and efficient GMP protocols. Moreover, the emergence of the COVID-19 breakdown added to the complexity of implementing standardization. Cell- and tissue-based therapies are completely dependent on the biological manifestations and parameters associated to and induced by this virus where the scope is still unknown. The initial flow chart identified for stem cell therapies should be reformulated and updated to overcome patient infection and avoid significant variability, thus enabling more patient safety and therapeutic efficiency. The aim of this work is to highlight the major guidelines and differences in ADSC processing meeting the current good manufacturing practices (cGMP) and the cellular therapy-related policies. Specific insights on standardization of ADSCs proceeding at different check points are also presented as a setup for the cord blood and bone marrow. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink